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Structured Summary  
 
Aims 
Co-trimoxazole maintains a well-established role in the treatment of Pneumocystis jirovecii 
and Toxoplasma gondii, as well as urinary tract infections. Observational studies report 
hyperkalemia associated with co-trimoxazole which may stem from an amiloride-like 
potassium sparing effect. Our study reports on changes in serum potassium on patients 
without acute infections, and the influence of concomitant anti-kaliuretic drugs on this effect. 
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Methods 
Post-hoc analysis of a randomised controlled trial in patients with interstitial lung disease 
who were assigned to placebo or 960 mg twice daily co-trimoxazole. Serum potassium and 
creatinine were measured at baseline, six weeks, 6, 9 and 12 months. Primary outcome was 
difference in mean serum potassium concentrations between co-trimoxazole and placebo at 
six weeks. 
 
Results  
Mean serum potassiums were similar at baseline, 4.24 (± 0.44) mmol/L in the 87 co-
trimoxazole group participants and 4.25 (± 0.39) mmol/L in the 83 control participants. Co-
trimoxazole significantly increased mean serum potassium at 6 weeks, difference between 
means compared to placebo of 0.21 mmol/L (95% Confidence Intervals [CI] 0.09-0.34; 
p=0.001). This significant increase in serum potassium was detectable even after exclusion of 
patients on anti-kaliuretic drugs, difference between means for co-trimoxazole compared to 
placebo 0.23 mmol/L (95% CI 0.09-0.38, p=0.002). There were 5/87 (5.7%) patients on co-
trimoxazole whose serum potassium reached concentrations ≥5.5 mmol/L during the study 
period. 
 
Conclusions 
Co-trimoxazole significantly increases serum potassium concentration, even in participants 
not using anti-kaliuretic drugs. Whilst the magnitude of increase is often minor, a small 
proportion in our outpatient cohort developed hyperkalaemia of clinical importance.  
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What is already known about this subject 
 
 Co-trimoxazole has an established role in treating urinary tract, Pneumocystis 
jirovecii and Toxoplasma gondii infections. 
 Observational studies have suggested combination of co-trimoxazole and anti-
kaliuretic medications is associated with sudden death through the mechanism of 
severe hyperkalaemia. 
 There are no placebo-controlled randomised trials with serum potassium results to 
demonstrate these changes. 
 
What this study adds 
 
 Our trial demonstrates significant serum potassium rise in co-trimoxazole users 
compared to placebo.  
 These findings remained in a separate analysis accounting for patients prescribed 
concomitant anti-kaliuretic medications. 
 The magnitude of increase was not large, however would be of importance to patients 
with serum potassium at the higher end of normal. 
Introduction 
 
Co-trimoxazole (a combination antibiotic of trimethoprim and sulfamethoxazole) is a 
commonly used treatment in the United States for urinary tract infections[1] and a reported 
4000 prescriptions a month are dispensed in Canada. Following concerns in the United 
Kingdom of antibiotic-related Clostridium difficile colitis from other broad-spectrum 
antibiotics, co-trimoxazole is regaining favor[2] and maintains a well-established role in the 
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treatment and prophylactic measures for Pneumocystis jirovecii and Toxoplasma gondii 
infection[3].  
 
Its link to hyperkalaemia lies in trimethoprim’s mechanism of action, which has been 
described by laboratory and animal studies as that akin to the potassium sparing effect of 
amiloride, where sodium channel activity is inhibited [4-6]. Earlier studies identified that 
those with more inherent defects in potassium homeostasis, had a higher risk of exacerbating 
this antikaliuretic effect, these included patients with acquired immunodeficiency 
syndrome[7] and acutely unwell hospitalized patients with mild renal insufficiency [4, 5, 8]. 
Recently there has been a significant focus of literature on evaluating the effects of 
concomitant medication such as inhibitors of renin-angiotensin system [9, 10], spironolactone 
[11] and beta-adrenoceptor antagonists [12] on precipitating sudden, severe hyperkalaemia, 
which might be a mechanism behind increased risk of sudden death in co-trimoxazole users, 
especially in elderly patients. It is speculated that the drug interaction with co-trimoxazole 
may exacerbate the amiloride-like inhibition of sodium channels in the luminal membrane of 
the distal tubule resulting in impaired potassium secretion.  
 
However, much of the data are observational in nature[9, 11], and few studies have had 
access to or reported serum potassium levels obtained through protocolised long-term follow-
up in a high quality randomised controlled trial. We undertook a post-hoc analysis of a 
placebo-controlled randomised controlled trial with 12 months follow-up to evaluate the 
effect of standard dose co-trimoxazole on the serum potassium concentrations. We also 
aimed to evaluate the change in serum potassium concentrations in separate subgroups of 
participants according to baseline history of concomitant medications that can increase serum 
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potassium concentrations, namely angiotensin converting enzyme inhibitors (ACE I), 
angiotensin II receptor blockers (ARB) and potassium sparing diuretics. 
 
Methods 
 
This study is a post-hoc analysis of a multicenter randomised placebo-controlled double-
blinded parallel arm trial of the use of co-trimoxazole for the treatment of idiopathic 
pulmonary fibrosis. Briefly, the trial recruited patients from 28 university and district 
hospitals in England and Wales between January 2008 and 2009. Patients randomised to the 
treatment arm received the standard dose of 960 mg (two tablets of 480 mg each) twice daily 
of co-trimoxazole (320 mg trimethoprim, 1600 mg sulfamethoxazole) plus folic acid. 
Controls were supplied identical placebos and folic acid. Laboratory testing, including urea 
and electrolytes were performed at baseline and assessed at 6 weeks, 6, 9 and 12 months as 
part of the safety monitoring of the study. The full methodology is reported in Shulgina et al. 
[13]. Research ethics was obtained from the Cambridgeshire 4 Research Ethics Committee 
[reference number: 07/MRE05/45]. The study was adherent to the Declaration of Helsinki 
and conducted in accordance with good clinical practice. Safety of the trial was monitored by 
independent oversight committees (Data Monitoring and Ethics Committee (DMEC) and 
Trial Steering Committee (TSC)) who had access to all serious adverse events (SAEs) 
reporting and withdrawals. All patients gave written informed consent. Age, gender, co-
morbidities and concurrent medications were recorded at baseline.  
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The primary outcome of the trial was change in forced vital capacity (FVC) after 12 months. 
For this post-hoc analysis, the main outcome of interest was the first follow-up serum 
potassium measurement at six weeks after study entry. Secondary outcomes included serum 
potassium concentrations at later time points, as well as serum creatinine concentrations. 
 
A. Statistical analysis 
 
All analyses were conducted using IBM SPSS Statistics 22. We calculated mean values and 
standard deviations (SD) for serum potassium and creatinine concentrations over the study 
period at each measurement point.  We assessed homogeneity of variance using Levene’s test 
and used the independent t-test to evaluate differences between the two intervention arms. 
For categorical adverse events, we used the chi-squared test to evaluate differences between 
groups. Pearson’s correlation coefficient was used to describe the relationship between two 
continuous variables in the trial participants. 
The main outcome was the difference in mean potassium concentrations between the 
treatment and placebo groups at the 6-week follow-up. We also calculated change in 
potassium concentrations against baseline at all time points for each individual patient, and 
compared the mean change between the two groups.  
In a pre-planned analysis, we evaluated the primary outcome in subgroups of patients who 
were, or were not using drugs that retain potassium (ACE I, ARB and potassium sparing 
diuretics) at baseline. 
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Results 
 
One hundred and eighty-one patients were enrolled onto the original study. Eighty-six 
patients were randomised into the placebo group and ninety-five into the treatment group. 
These groups were stratified for azathioprine and mycophenolate mofetil use only. Table 1 
summarizes the baseline characteristics of patients included in the complete case analysis, 
where both baseline and 6-week follow-up potassium were available in included patients. 
Appendix 1 lists the baseline characteristics of the entire treatment and placebo group. 
Baseline mean potassium, serum creatinine and the number of patients taking medications 
which could alter potassium homeostasis were in equal distribution. All patients enrolled in 
the study provided a serum potassium and creatinine level at baseline. The availability of 
follow-up data diminished as the study progressed, due to adverse events, discontinuation of 
interventions and withdrawal of consent, n=83, 65, 57 and 54 in the placebo group at 6 
weeks, 6 months, 9 months and 12 months respectively whilst in the treatment group n= 87, 
63, 51, 53 were available at those time points. Blinded interim analysis showed no significant 
difference in the percentage of patients dying, average number of adverse or serious adverse 
events between the two groups.  
 
A. Main Outcome: Difference in Means Between Groups 
At the six-week follow-up, the mean serum potassium concentration in the treatment group 
(4.46 ±0.41 mmol/L) was significantly higher than the mean in the placebo group (4.24 ±0.40 
mmol/L), which represents a difference between means of 0.21 (95% CI 0.09-0.34) mmol/L, 
p=0.001. 
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The mean serum potassium concentrations recorded at the four study follow-up visits are 
shown in Figure 1 and Appendix 2. The change from baseline serum potassium data are 
shown in Figure 3 and Appendix 3, and indicate significant incremental rises in serum 
potassium with co-trimoxazole compared to placebo at all follow-up points. 
 
The largest increase in the serum potassium of the entire trial was 1.7 mmol/L, which was 
recorded in a patient receiving co-trimoxazole. We found that 15/87 (17%) patients on co-
trimoxazole experienced a change of ≥ +1mmol/L serum potassium at any point in the study 
compared to 3/83 (3.6%) in the control arm. The relative risk of a rise ≥ +1mmol/L serum 
potassium with co-trimoxazole is 4.77 (95% CI 1.43 – 15.88) compared to placebo. 
We found that 25/87 (29%) of patients in the treatment group had a peak serum potassium 
≥5.0 mmol/L at any point of follow up, compared to 15/83 (18%) patients in the control arm. 
The relative risk of serum potassium ≥5.0 mmol/L at any point in the trial was 1.59 (95% CI 
0.90 – 2.80) with co-trimoxazole compared to placebo. 
 
Overall, 5/87 (5.7%) patients in the co-trimoxazole arm had serum potassium ≥5.5 mmol/L, 
compared to 1/83 (1.2%) in the control arm. There were no reports of hyperkalemia as a 
cause of a serious adverse event or a reason for patient withdrawal.  
 
A pre-planned analysis on mean serum potassium at baseline to 6 weeks was performed on a 
subgroup of patients where we excluded baseline users of ACE inhibitors (ACEI), 
Angiotensin II receptor blockers (ARB) or Potassium sparing diuretics (n=28). Figure 2 
illustrates our finding of a significant increase in serum potassium concentrations in the 
treatment group compared to placebo, 0.23 mmol/L (95% CI 0.09-0.38, p=0.002), even in the 
absence of concomitant use of drugs that have been implicated in hyperkalemia. When we 
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considered the small subgroup comprising users of ACEI, ARB or potassium sparing 
diuretics, the difference in mean potassium concentrations between co-trimoxazole and 
placebo arms was not statistically significant (0.14 mmol/L (95% CI -0.10-0.38) p=0.24). 
 
B. Secondary Outcomes 
Figure 3, Appendix 2 and Appendix 3 illustrate the mean serum creatinine concentrations 
in treatment and placebo group at 6 weeks, 6, 9 and 12 months. At the six-week follow-up, 
the mean serum creatinine concentration in the treatment group (105.79 ±33.43mmol/L) was 
significantly higher than the mean in the placebo group (89.81 ±18.10mmol/L), which 
represents a difference between means of 15.99 (95% CI 7.88-24.09) mmol/L, p=0.005. 
The elevation in creatinine was persistent at further follow-up measurements. (Appendix 2 
and 3). We found a moderate positive correlation between change from baseline in potassium 
and creatinine concentrations at 6 weeks, r(168)=0.383, p<0.0005. 
 
C. Renal Adverse Events 
On reviewing reported adverse events in patients in the co-trimoxazole group, 10/95 patients 
(11%) of patients were reported to have a deterioration in renal function compared to 3/86 
(3.5%) in the placebo group (p=0.78). Here, 7 of the 10 patients in the co-trimoxazole group 
went on to complete the study whilst 3 of the 10 patients were unable to continue after the 6-
week follow-up. Serum creatinine was on a downward trend for these patients on follow-up 
testing up to 2 months later. Renal impairment was specifically mentioned in the original 
study publication, however individual electrolytes have never before been published.  
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Discussion 
 
Main Findings 
 
In this post-hoc analysis of a blinded, placebo-controlled, randomised controlled trial we 
demonstrate a significant increase in measured serum potassium at 6 weeks in patients taking 
co-trimoxazole as compared to those on placebo. We note that the significant increase in 
serum potassium concentrations occurred even in patients who were not taking concomitant 
ACEI, ARBs or potassium sparing diuretics with co-trimoxazole, thus indicating that this 
adverse effect is not due to a specific drug interaction. While the magnitude of increase was 
clinically modest in most patients, we found that about 1 in 7 patients in the treatment group 
were affected by increases of  1.0 mmol/L.  About 1 in 25 patients receiving co-trimoxazole 
had a peak serum potassium that exceeded 5.5 mmol/L, which is a concentration that we 
would consider to be of major clinical concern. We also noted a concurrent increase in serum 
creatinine with co-trimoxazole therapy within the first six weeks of starting treatment.  
 
Comparison with Literature 
 
Co-trimoxazole has been linked to sudden death through the postulated mechanism of 
precipitating life-threatening hyperkalemia. The exact renal mechanism has been previously 
described[4], through human and animal studies. Trimethoprim inhibits renal potassium 
excretion by blocking sodium channels in the distal nephron and decreasing the electrical 
driving force favoring potassium secretion. We report findings which can be attributed to the 
described mechanism. There is a significant rise in mean serum potassium at 6 weeks 
followed by a sustained increase from baseline at the further three points of serial potassium 
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measurements. This trend appears to be replicated in serum creatinine. Rise in serum 
creatinine is secondary to a well described mechanism related to the trimethoprim component 
of co-trimoxazole which competitively inhibits tubular creatinine secretion[14]. Previous 
studies have demonstrated a rise in serum creatinine with concomitant fall in creatinine 
clearance and no significant change in glomerular filtration rate (GFR) [15]. The mechanism 
of the moderate correlation between increase in potassium and creatinine concentrations are 
not clear, and further research into the possibility of a nephrotoxic effect may be indicated. 
 
Four large population studies have examined this life-threatening complication of 
hyperkalemia, thought to be induced by a drug-interaction with co-trimoxazole. Antoniou et 
al. has reported the highest risk of hospital admission[11] with hyperkalemia or sudden death 
[16] in patients concurrently taking spironolactone. The same group has also reported a 
higher risk of hospitalization with hyperkalemia and sudden death in patients taking co-
trimoxazole alongside inhibitors of renin-angiotensin system in comparison to patients 
prescribed other antibiotics. This reaction is thought to be linked to the amiloride properties 
of trimethoprim, which are further perpetuated by the antagonistic effects of ACEI, ARB and 
potassium sparing diuretics on aldosterone. In contrast, our study has not demonstrated 
evidence of life threatening serum potassium concentrations across all patients, even in those 
taking medications whose mechanisms of action involve aldosterone.  
The strength of previous studies lies in their large numbers captured in electronic databases 
over a significant period of time. However, none of these studies had access to serum 
potassium measurements. There also remains an important question of whether confounding 
has been entirely accounted for in the previous observational datasets.  
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Strengths and Limitations 
 
Unlike our current work, few studies have had access to serial serum potassium 
measurements in a protocolised manner with a randomised controlled trial. A large analysis 
of 6162 patients prescribed high and standard dose co-trimoxazole[17] has been reported, 
however serum potassium measurements in this study were recorded if available at variable 
times up to 30 days after the initial prescription was made, making it difficult to comprehend 
what context the serum potassium was measured in. Similarly a retrospective analysis of 53 
patients’ serum potassium whilst on co-trimoxazole[18] has shown significant (p=0.017) 
increase of serum potassium to mean of 4.67 mmol/L. Again, serum potassium recordings 
were taken within 5 days of prescription or as close to, with no knowledge of the patient’s 
medical situation at the time.  To our knowledge, there has only been one randomised 
controlled trial with prospective serum potassium measurements[19]. This was an un-blinded 
randomised controlled trial of 97 outpatients where patients randomised to the control group 
were those treated with other antibiotics. All patients in this study had one follow up serum 
urea and electrolyte measurements on day 5 of treatment. Only 6% (n=3) of their cohort 
developed severe hyperkalemia  5.5 mmol/L, which is comparable to the 2.6% of patients in 
the Gentry et al.[17] study who developed grade 1 hyperkalemia (5.6-6.0 mmol/L). Unlike 
our study, this study was not blinded, and patients were receiving active control drugs rather 
than placebo. 
 
Our study’s results are comparable to those who have reported on serum potassium 
measurements in an outpatient setting. This study builds on those previously described as it 
has been performed on well patients, with no acute infections, in a blinded, randomised, 
placebo-controlled setting. We are able to individually account for all potassium-altering 
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medications in each patient and for the first time report on the sustained, longer term effects 
of co-trimoxazole on a patient’s serum potassium and creatinine. We recognize our study is 
limited by the smaller sample size, time-varying effect and losses to follow-up that led to 
fewer available serum potassium measurements as the study progressed. However, we are 
able to definitively report that the withdrawal of patients has not been precipitated by 
clinically relevant hyperkalemia. Only 3 of the 10 patients with reported renal deterioration 
were unable to complete the study after 6 weeks. It was also reassuring to note the 
improvement in their renal function after withdrawal from treatment, confirming the 
reversible nature of the impairment. Finally, we did not have sufficient numbers of patients 
with markedly elevated potassium concentrations for us to be able to reliably identify the 
patient risk factors that predispose to this adverse effect. The mean age of the co-trimoxazole 
group was 72.38 (SD 8.45); we were unable to investigate the effect of age on the increase in 
serum potassium. As the study population was older, this may be in itself a contribution to a 
larger increase in serum potassium, independent of concomitant anti-kaliuretic medication 
use. It is possible that there is an underlying genetic predisposition that renders some patients 
susceptible to hyperkalemia with co-trimoxazole, but this trial was not designed to investigate 
such pharmacogenetic markers.  
 
Conclusion 
 
Over our study, we did not identify a significant risk of patients developing life-threatening 
hyperkalemia, even with up to a year’s exposure; nor did we find evidence of an interaction 
with anti-kaliuretic agents. However, we are conscious that a small minority of patients 
experienced potassium elevations to a degree that may raise clinical concern. Therefore, there 
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should be far greater caution in those who already have serum potassium concentrations at 
the top end of the normal range.  
 
TIPAC investigators are listed in alphabetical order in Appendix 4.  
 
Statement of competing financial interests: APC (a TIPAC investigator) is an employee of 
GlaxoSmithKline but has no conflict of interest to declare.  
 
Table of Links: 
 
TARGETS 
 
 
G-protein-coupled 
receptor [21] 
 
Enzymes [24] 
 
Angiotensin Receptor Angiotensin Converting 
Enzyme 
 
β1-adrenoceptor Cyclooxygenase 1 
 
Nuclear Hormone 
Receptor [22] 
 
Cyclooxygenase 2 
Glucocorticoid receptor Dihydrofolate Reductase 
 
Mineralocorticoid 
receptor  
 
Thymidylate Synthetase 
 
Transporters [23] 
 
Ion channels [25] 
Kidney-Specific Na-K-
Cl symporter 
Calcium-activated 
potassium channel 
subunit alpha-1 
 
Na-Cl symporter 
 
 
 
 
These Tables list key protein targets in this article that are hyperlinked to corresponding 
entries in http://www.guidetopharmacology.org, the common portal for data from the 
IUPHAR/BPS Guide to PHARMACOLOGY [20], and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 [21-25]. 
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Table 1: Baseline Characteristics of complete case analysis 
Characteristic Placebo (n=83) 
Co-trimoxazole 
(n=87) 
  
Mean/number 
(SD/%) 
Mean/number 
(SD/%) 
Age, years                 Mean ±SD              70.86 (8.25) 72.54 (8.45) 
Number or women (%) 20 (24.1) 29 (33.3) 
Number of patients with hypertension (%) 22 (26.5) 19 (21.8) 
Number of patients taking potassium-altering drugs (%) 66 (76.7) 61 (64.2) 
                     ACE inhibitor 13 (15.7) 13 (14.9) 
                     Angiotensin Receptor Blocker 8 (9.6) 15 (17.2) 
                     Potassium Sparing Diuretics 0    (0) 1   (1.1) 
                     Potassium Supplement 0    (0) 1    (1.1) 
                     Loop Diuretics 10 (12.0) 15 (17.2) 
                     Thiazide Diuretics 5    (6.0) 7    (8.0) 
                     Aspirin 27  (32.5) 33 (37.9) 
                     NSAID (not including aspirin) 1     (1.2) 1     (1.1) 
                     Beta-adrenoceptor antagonists 15   (18.1) 13  (14.9) 
                     Prednisolone 51  (61.4) 49 (56.3) 
Mean K+ concentration, mmol/L (SD) 4.25 (0.39) 4.24 (0.43) 
Mean serum creatinine level, mmol/L (SD) 89.0 (21.8) 88.96 (25.0) 
SD - standard deviation, CI - Confidence Intervals     
NSAID - non-steroidal anti-inflammatory drug, ACE - angiotensin converting enzyme 
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Figure 1: Mean Serum Potassium in Co-Trimoxazole and Placebo Arms 
llustrated error bars depict the standard error of each measurement. 
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Figure 2: Mean Serum Potassium in users and non-users of ACEi, ARB or K+ sparing 
diuretic users at baseline and 6 weeks. 
Illustrated error bars depict the standard error of each measurement
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Figure 3: Mean Serum Creatinine in Co-Trimoxazole and Placebo Arms 
Illustrated error bars depict the standard error of each measurement 
